- Home
- NXTT vs BLRX Comparison
NXTT vs BLRX Comparison
Compare NXTT & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTT
- BLRX
- Stock Information
- Founded
- NXTT 2019
- BLRX 2003
- Country
- NXTT China
- BLRX Israel
- Employees
- NXTT N/A
- BLRX N/A
- Industry
- NXTT
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- NXTT
- BLRX Health Care
- Exchange
- NXTT NYSE
- BLRX Nasdaq
- Market Cap
- NXTT 19.5M
- BLRX 17.3M
- IPO Year
- NXTT N/A
- BLRX 2011
- Fundamental
- Price
- NXTT $1.31
- BLRX $3.59
- Analyst Decision
- NXTT
- BLRX Strong Buy
- Analyst Count
- NXTT 0
- BLRX 2
- Target Price
- NXTT N/A
- BLRX $220.00
- AVG Volume (30 Days)
- NXTT 334.1K
- BLRX 154.8K
- Earning Date
- NXTT 04-15-2025
- BLRX 03-25-2025
- Dividend Yield
- NXTT N/A
- BLRX N/A
- EPS Growth
- NXTT N/A
- BLRX N/A
- EPS
- NXTT 3.59
- BLRX N/A
- Revenue
- NXTT $1,133,308.00
- BLRX $21,991,000.00
- Revenue This Year
- NXTT N/A
- BLRX N/A
- Revenue Next Year
- NXTT N/A
- BLRX N/A
- P/E Ratio
- NXTT $0.37
- BLRX N/A
- Revenue Growth
- NXTT N/A
- BLRX N/A
- 52 Week Low
- NXTT $0.94
- BLRX $3.20
- 52 Week High
- NXTT $6.66
- BLRX $57.60
- Technical
- Relative Strength Index (RSI)
- NXTT 41.83
- BLRX 36.94
- Support Level
- NXTT $1.03
- BLRX $3.26
- Resistance Level
- NXTT $1.23
- BLRX $4.17
- Average True Range (ATR)
- NXTT 0.15
- BLRX 0.28
- MACD
- NXTT 0.03
- BLRX 0.24
- Stochastic Oscillator
- NXTT 66.67
- BLRX 36.26
About NXTT NEXT TECHNOLOGY HOLDING INC
Next Technology Holding Inc pursues two corporate strategies. One business strategy is to continue providing software development services, and the other strategy is to acquire and hold Bitcoin. It provides AI-enabled software development services to its customers, which include developing, designing, and implementing various SAAS software solutions for businesses of all types, including industrial and other businesses. Its bitcoin acquisition strategy generally involves acquiring bitcoin with its liquid assets that exceed working capital requirements, and from time to time, subject to market conditions, issuing debt or equity securities or engaging in other capital raising transactions to use the proceeds to purchase bitcoin.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.